• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates

Stratatech Corp.

FDA approves Stratatech’s StrataGraft skin graft

June 15, 2021 By Danielle Kirsh

Mallinckrodt‘s (NYSE: MNK) Stratatech today received FDA approval for its StrataGraft for treating adult patients with thermal burns. The Bedminister, N.J.-based company designed StrataGraft to treat thermal burns that have intact dermal elements, or remaining deep skin layers, for which surgical intervention is clinically indicated. “Serious burns can be an incredibly difficult injury to treat and can […]

Filed Under: Food & Drug Administration (FDA), Regenerative Medicine, Regulatory/Compliance Tagged With: Mallinckrodt, Stratatech Corp.

BARDA adds $26m to Stratatech’s StrataGraft development deal

October 17, 2018 By Fink Densford

Mallinckrodt‘s (NYSE: MNK) Stratatech has won an additional $26 million in Project BioShield funding from the the U.S. Biomedical Advanced Research and Development Authority to support pediatric studies of its StrataGraft engineered skin tissue. The funding will support continued development of the StrataGraft as a potential medical countermeasure for large-scale burn incidents, U.K.-based Mallinckrodt said. BARDA previously supplied […]

Filed Under: Business/Financial News, Featured, Regenerative Medicine, Wound Care Tagged With: Mallinckrodt, Stratatech Corp.

Covidien spinout Mallinckrodt to acquire Stratatech

August 11, 2016 By Brad Perriello

Mallinckrodt plc (NYSE: MNK) said today that it agreed to acquire Stratatech and its StrataGraft artificial skin graft technology for an undisclosed amount. Mallinckrodt, the pharmaceuticals business spun out of Covidien in 2013, said the deal also includes Stratatech’s development program for genetically enhanced skin. The acquisition is expected to close before the end of the year, the Dublin-based company […]

Filed Under: Mergers & Acquisitions, Regenerative Medicine, Wall Street Beat, Wound Care Tagged With: Covidien, Mallinckrodt, Stratatech Corp.

Stratatech scores BARDA deal worth up to $247m

October 5, 2015 By Fink Densford

Stratatech said it won a contract from the Biomedical Advanced Research and Development Authority worth up to $247 million to develop its StrataGraft skin tissue designed for patients with severe thermal burns. The 5-year structured BARDA contract grants an initial $60 million for the “base period” and to procure the eventual-finished StrataGraft product to establish an inventory […]

Filed Under: Business/Financial News, Regenerative Medicine, Stem Cells Tagged With: Stratatech Corp.

J&J shareholders make noise | MassDevice.com On Call

April 30, 2012 By MassDevice staff Leave a Comment

MassDevice On Call

MASSDEVICE ON CALL — Shareholders at Johnson & Johnson‘s (NYSE:JNJ) annual meeting had much to say about the company’s recent slew of high-profile product quality issues.

Filed Under: News Well, Recalls, Regenerative Medicine, Wall Street Beat Tagged With: Johnson and Johnson, On Call, Renal, Stratatech Corp.

Diabetes: Stratatech lands $4.6 million to study antimicrobial skin graft for diabetic foot ulcers | Funding Roundup

November 1, 2011 By MassDevice staff Leave a Comment

ExpressGraft

Stratatech’s ExpressGraft

Stratatech Corp. won a $4.6 million grant to run a clinical trial from the National Institute of Diabetes & Digestive & Kidney Diseases.

The funds will support the first human study of Stratatech’s ExpressGraft Antimicrobial genetically engineered living skin substitute as a therapy for diabetic foot ulcers.

Filed Under: Funding Roundup, News Well Tagged With: CerviLenz, HyperBranch Medical Technologies, MiMedx Group Inc., Neuros Medical Inc., Sensors for Medicine and Science Inc., Stratatech Corp.

Stratatech lands $4.6 million to study antimicrobial skin graft

November 1, 2011 By MassDevice Leave a Comment

Stratatech Awarded $4.6-Million Clinical Trial Grant for ExpressGraft™ Antimicrobial Skin Substitute

MADISON, Wis.–(BUSINESS WIRE)–Stratatech Corp., a leader in regenerative medicine, today announced that the company has been awarded a $4.6-million grant by the National Institute of Diabetes and Digestive and Kidney Diseases to support the first human clinical trial of Stratatech’s ExpressGraft™ antimicrobial skin substitute. The clinical trial will assess the safety and efficacy of the tissue as a treatment for chronic diabetic foot ulcers. This pioneering product is the first therapeutic skin substitute to be genetically enhanced to fight infection and accelerate wound healing.

Filed Under: Funding Roundup, Regenerative Medicine Tagged With: Press Release, Stratatech Corp.

Calgary Scientific’s iPhone app receives FDA clearance | Regulatory Roundup

September 27, 2011 By MassDevice staff Leave a Comment

CalgaryScientific

Calgary Scientific’s ResolutionMD mobile got a green light from the FDA for viewing diagnostic images on iPhones and iPads.

The ResolutionMD mobile app was built from existing ResolutionMD software, which recieved FDA clearance in 2006. The app already has the greenlight from Canada’s regulatory body, Health Canada and has a CE Mark for distribution in Europe.

Filed Under: Food & Drug Administration (FDA), News Well Tagged With: Avinger, Calgary Scientific, Eye on the FDA, IRIS International Inc., Regulatory Roundup, Sapheon Inc, Stratatech Corp., uptakemedical

Stratatech Initiates Second Clinical Trial of StrataGraft Skin Substitute

September 26, 2011 By MassDevice Leave a Comment

Stratatech Initiates Second Clinical Trial of StrataGraft® Skin Substitute

MADISON, Wis.–(BUSINESS WIRE)–Stratatech Corp., a leader in regenerative medicine, today announced that it has initiated its second multicenter clinical trial of the company’s StrataGraft® skin substitute. The clinical trial will assess the safety and clinical utility of the StrataGraft® skin substitute in the long-term treatment of patients with severe second-degree burns.

“We achieved our primary endpoints during StrataGraft’s Phase I clinical trial, which were related to safety and efficacy, and obtained important insights into the immunological response of patients with severe third-degree burns”

Filed Under: Uncategorized Tagged With: Stratatech Corp.

Stratatech wins $4 million in defense funding for living skin substitute

October 8, 2010 By MassDevice staff Leave a Comment

Stratatech logo

Stratatech Corp. won $3.95 million from the U.S. Dept. of Defense’s Armed Forces Institute of Regenerative Medicine.

The Madison, Wis.-based company said the AFIRM cash will fund the Phase IIb clinical trial of its StrataGraft cell-based, tissue-engineered skin substitute.

Filed Under: Biotech, Business/Financial News, News Well, Regenerative Medicine Tagged With: Stratatech Corp.

Stratatech plans clinical trial for skin substitute

May 5, 2010 By MedCity News Leave a Comment

MedCity News logo

By Brandon Glenn

Fresh off a $3 million funding round, Stratatech Corp. plans to begin Phase IIb clinical trials of its genetically engineered human skin substitute.

Filed Under: Biotech, Business/Financial News, Contract Manufacturing, News Well Tagged With: Stratatech Corp.

  • Go to page 1
  • Go to page 2
  • Go to Next Page »

Primary Sidebar

DeviceTalks Weekly

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS